Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper. Traditionally, most biotech stock drug candidates fail. Indeed, according to Nature, “An estimated 86% of drug candidates developed between 2000 and 2015 did not meet their stated endpoints.” And the well-respected consulting firm McKinsey reported that “Today, to discover and develop a drug takes more than ten years.”
Meanwhile, AI can cut that same time frame down to just one year. That being said, investors may want to pay close attention to these top three biotech stocks to buy and hold.
This post appeared first on InvestorPlace.